Pegfilgrastim biosimilar - Adello Biologics

Drug Profile

Pegfilgrastim biosimilar - Adello Biologics

Alternative Names: TPI-120

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therapeutic Proteins International
  • Developer Adello Biologics
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neutropenia

Most Recent Events

  • 25 Mar 2017 Phase-I clinical trials in Neutropenia (In volunteers) in USA (SC) (NCT03202927)
  • 13 Feb 2017 Adello Biologics initiates a phase I trial in Healthy volunteers in USA (SC) (NCT03206229)
  • 16 Nov 2016 Therapeutic Proteins International is now called Adello Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top